Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04613596 : A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab Plus Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

Two/ThreePhase Two/Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungNon-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This Phase II/III study is evaluating how safe and effective a new targeted therapy (MRTX849) is alone, and in combination with immunotherapy (pembrolizumab), in people with advanced or metastatic non-small cell lung cancer with KRAS G12C mutation.
 

This trial is treating patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutation.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab Plus Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Commercial Sponsor

Mirati Therapeutics Inc.

Summary

This study is being conducted in two parts, and each part has multiple cohorts of participants. The Phase II portion of the study will evaluate the efficacy and safety of MRTX849 as monotherapy and when given in combination with pembrolizumab. There will be 3 cohorts of participants, all of whom have KRAS G12C mutation, have advanced or metastatic non-small cell lung cancer (NSCLC), and are candidates for first-line treatment. 2 cohorts of people who have a PD-L1 TPS score of <1% and="" are="" randomised="" to="" receive="" either="" mrtx849="" as="" monotherapy="" or="" mrtx849="" in="" combination="" with="" pembrolizumab.="" the="" 3rd="" cohort="" will="" consist="" of="" people="" with="" pd-l1="" score="" of="" 1%="" or="" higher,="" and="" they="" will="" receive="" mrtx849="" +="" pembrolizumab.="" the="" phase="" iii="" portion="" of="" the="" study="" will="" randomise="" people="" with="" non-squamous="" nsclc="" with="" kras="" g12c="" mutation="" and=""><50% in="" the="" first-line="" setting="" to="" receive="" either="" mrtx849="" +="" pembrolizumab,="" or="" pembrolizumab="" +="" chemotherapy.="" **note:="" in="" april="" 2023,="" grampians="" health="" is="" recruiting="" only="" people="" with="" pd-l1="" tps="" of=""><>

Recruiting Hospitals Read MoreRead more

Grampians Health
Ballarat
Ms Carmel Goss
CarmelG@bhs.org.au
03 5320 4735

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next